Flare After Switching from Intravenous Tocilizumab to Subcutaneous Formulation in Patients with Rheumatoid Arthritis

被引：0
|
作者：
Ahn, Soo Min [1 ]
Oh, Ji Seon [2 ]
Heo, Hyun Mi [3 ]
Hong, Seokchan [3 ]
Lee, Chang-Keun [3 ]
Yoo, Bin [1 ]
Kim, Yong-Gil [3 ]
机构：
[1] ASAN Med Ctr, Seoul, South Korea
[2] Asan Med Ctr, Ulsan, South Korea
[3] Asan Med Ctr, Seoul, South Korea
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0836
引用
收藏
页码：1728 / 1730
页数：3
相关论文
共 50 条
  • [41] Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients
    Monti, Sara
    Breda, Silvia
    Grosso, Vittorio
    Todoerti, Monica
    Montecucco, Carlomaurizio
    Caporali, Roberto
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (10) : 1993 - +
  • [42] Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: A case series
    Talotta R.
    Atzeni F.
    Batticciotto A.
    Ditto M.C.
    Gerardi M.C.
    Sarzi-Puttini P.
    Journal of Medical Case Reports, 12 (1)
  • [43] EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS OVERLAP SYNDROME
    Wakabayashi, H.
    Kino, S.
    Hasegawa, M.
    Sudo, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1518 - 1519
  • [44] CLINICAL EFFICACY OF TNF INHIBITORS AND ABATACEPT IN JAPANESE RHEUMATOID ARTHRITIS PATIENTS SWITCHING FROM TOCILIZUMAB
    Hirabara, S.
    Kojima, T.
    Takahashi, N.
    Yabe, Y.
    Kaneko, A.
    Kida, D.
    Hirano, Y.
    Ishiguro, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1057 - 1058
  • [45] Bridging from the Intravenous to Subcutaneous Formulation of Tocilizumab for Polyarticular Juvenile Idiopathic Arthritis and Systemic Juvenile Idiopathic Arthritis by Leveraging Prior Pharmacometrics Knowledge
    Hsu, Joy C.
    Gibiansky, Leonid
    Bharucha, Kamal
    Kadva, Alysha
    Kamal, Mohamed
    Mallalieu, Navita
    Frey, Nicolas
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S104 - S104
  • [46] DISCONTINUATION OF TOCILIZUMAB AFTER ATTAINING REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Nampei, A.
    Nagayama, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 877 - 877
  • [47] Therapeutic Drug Monitoring on Rheumatoid Arthritis Patients with Reduced Doses of Intravenous Tocilizumab
    Ruiz-Esquide, Virginia
    Bastida, Carla
    Pascal, Mariona
    Yague, Jordi
    Soy, Dolors
    Sanmarti, Raimon
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [48] AN ANALYSIS OF INCREASING SPACING TIME FOR THE INTRAVENOUS ADMINISTRATION OF TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Ito, S.
    Kobayashi, D.
    Takai, C.
    Nomura, Y.
    Abe, A.
    Otani, H.
    Ishikawa, H.
    Murasawa, A.
    Narita, I.
    Nakazono, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 853 - 854
  • [49] EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS TOCILIZUMAB IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: 49 WEEK SUMMACTA DATA
    Burmester, Gerd R.
    Rubbert-Roth, Andrea
    Cantagrel, Alain
    Hall, Stephen
    Leszczynski, Piotr
    Feldman, Daniel
    Rangaraj, Madura J.
    Roane, Georgia
    Ludivico, Charles
    Mysler, Eduardo F.
    Wells, Chris
    Bennett, Melanie
    Vranic, Ivana
    RHEUMATOLOGY, 2014, 53 : 37 - 38
  • [50] THERAPEUTIC DRUG MONITORING ON RHEUMATOID ARTHRITIS PATIENTS WITH REDUCED DOSES OF INTRAVENOUS TOCILIZUMAB
    Ruiz-Esquide, V.
    Bastida, C.
    Pascal, M.
    Yague, J.
    Soy, D.
    Sanmarti, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 840 - 840
12345